Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 1
2005 2
2008 2
2009 1
2010 2
2011 3
2012 1
2013 6
2014 5
2015 1
2016 3
2017 4
2018 3
2019 6
2020 4
2021 12
2022 5
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Neuropilin 2 and soluble neuropilin 2 in neuroendocrine neoplasms.
Gerard L, Patte C, Chardon L, Hervieu V, Payen L, Allio M, Marx C, Clermidy H, Durand A, Mehlen P, Bollard J, Poncet G, Roche C, Gibert B, Walter T. Gerard L, et al. Among authors: payen l. Endocr Relat Cancer. 2024 May 10;31(6):e240052. doi: 10.1530/ERC-24-0052. Print 2024 Jun 1. Endocr Relat Cancer. 2024. PMID: 38642579
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial.
Puszkiel A, You B, Payen L, Lopez J, Guitton J, Rousset P, Fontaine J, Péron J, Maillet D, Tartas S, Bonnin N, Trillet-Lenoir V, Colomban O, Augu-Denechere D, Freyer G, Tod M. Puszkiel A, et al. Among authors: payen l. Cancer Chemother Pharmacol. 2023 May;91(5):413-425. doi: 10.1007/s00280-023-04520-z. Epub 2023 Apr 3. Cancer Chemother Pharmacol. 2023. PMID: 37010549 Clinical Trial.
Paired Comparison of Routine Molecular Screening of Patient Samples with Advanced Non-Small Cell Lung Cancer in Circulating Cell-Free DNA Using Three Targeted Assays.
Barthelemy D, Lescuyer G, Geiguer F, Grolleau E, Gauthier A, Balandier J, Raffin M, Bardel C, Bouyssounouse B, Rodriguez-Lafrasse C, Couraud S, Wozny AS, Payen L. Barthelemy D, et al. Among authors: payen l. Cancers (Basel). 2023 Mar 3;15(5):1574. doi: 10.3390/cancers15051574. Cancers (Basel). 2023. PMID: 36900363 Free PMC article.
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.
Varnier R, Puszkiel A, Tod M, Calattini S, Payen L, Lopez J, Guitton J, Schwiertz V, Fontaine J, Peron J, Maillet D, Tartas S, Bonnin N, Colomban O, Augu-Denechere D, Freyer G, You B. Varnier R, et al. Among authors: payen l. Cancer Chemother Pharmacol. 2023 May;91(5):361-373. doi: 10.1007/s00280-023-04508-9. Epub 2023 Feb 25. Cancer Chemother Pharmacol. 2023. PMID: 36840749 Clinical Trial.
Embryonated Chicken Tumor Xenografts Derived from Circulating Tumor Cells as a Relevant Model to Study Metastatic Dissemination: A Proof of Concept.
Rousset X, Maillet D, Grolleau E, Barthelemy D, Calattini S, Brevet M, Balandier J, Raffin M, Geiguer F, Garcia J, Decaussin-Petrucci M, Peron J, Benzerdjeb N, Couraud S, Viallet J, Payen L. Rousset X, et al. Among authors: payen l. Cancers (Basel). 2022 Aug 23;14(17):4085. doi: 10.3390/cancers14174085. Cancers (Basel). 2022. PMID: 36077622 Free PMC article.
[hPG80 and cancer: A new blood biomarker in development for patient monitoring].
You B, Assenat E, Payen L, Mazard T, Glehen O, Calattini S, Villeneuve L, Lescuyer G, Vire B, Ychou M. You B, et al. Among authors: payen l. Bull Cancer. 2022 Jun;109(6):707-713. doi: 10.1016/j.bulcan.2022.03.009. Epub 2022 May 18. Bull Cancer. 2022. PMID: 35597620 Free article. Review. French.
65 results